Eliquis is manufactured by Bristol Myers Squibb and Pfizer [1].
How do Bristol Myers Squibb and Pfizer collaborate on Eliquis?
Bristol Myers Squibb and Pfizer are co-developers and co-marketers of Eliquis. This partnership leverages the strengths of both pharmaceutical companies in the development, manufacturing, and commercialization of the anticoagulant medication [1].
What is the medical use of Eliquis?
Eliquis (apixaban) is a medication used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). It is also prescribed to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [2].
When does the patent for Eliquis expire?
The patent landscape for Eliquis is complex, with multiple patents covering different aspects of the drug. According to DrugPatentWatch.com, the earliest expected patent expiry for Eliquis is in the United States in 2026, with other key patents expiring later [3]. These patents are crucial for maintaining market exclusivity for the drug's manufacturers.
What are the potential alternatives to Eliquis?
Other anticoagulant medications are available for similar indications. These include warfarin, which is a vitamin K antagonist, and other direct oral anticoagulants (DOACs) such as rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) [4]. Each of these medications has its own efficacy, safety profile, and dosing requirements.